BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30886955)

  • 1. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).
    Ramanan AV; Dick AD; Jones AP; Guly C; Hardwick B; Hickey H; Lee R; McKay A; Beresford MW;
    BMC Rheumatol; 2018; 2():4. PubMed ID: 30886955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
    Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
    Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.
    Ramanan AV; Dick AD; Guly C; McKay A; Jones AP; Hardwick B; Lee RWJ; Smyth M; Jaki T; Beresford MW;
    Lancet Rheumatol; 2020 Mar; 2(3):e135-e141. PubMed ID: 32280950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
    Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
    Trials; 2014 Jan; 15():14. PubMed ID: 24405833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
    Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
    Thomas J; Kuthyar S; Shantha JG; Angeles-Han ST; Yeh S
    Ann Eye Sci; 2021 Jun; 6():. PubMed ID: 34131629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial.
    Acharya NR; Ebert CD; Kelly NK; Porco TC; Ramanan AV; Arnold BF;
    Trials; 2020 Oct; 21(1):887. PubMed ID: 33109240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Clin Immunol; 2020 Feb; 211():108322. PubMed ID: 31830532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review.
    Iannone C; Marelli L; Costi S; Pellico MR; La Franca L; Caporali R; Miserocchi E
    Children (Basel); 2023 Feb; 10(3):. PubMed ID: 36979992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile idiopathic arthritis-associated uveitis.
    Sen ES; Ramanan AV
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):517-534. PubMed ID: 29773271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
    Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B
    Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
    Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
    J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.
    Tappeiner C; Schenck S; Niewerth M; Heiligenhaus A; Minden K; Klotsche J
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):46-54. PubMed ID: 26212111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
    Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
    N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.
    Burlo F; Tumminelli C; Pastore S; Stocco G; Curci D; Lucafò M; Tommasini A; Taddio A
    Pediatr Rheumatol Online J; 2023 Sep; 21(1):99. PubMed ID: 37700264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis.
    Papadopoulou C; Kostik M; Böhm M; Nieto-Gonzalez JC; Gonzalez-Fernandez MI; Pistorio A; Martini A; Ravelli A
    J Pediatr; 2013 Sep; 163(3):879-84. PubMed ID: 23664559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
    Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
    Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.
    Calvo-Río V; Santos-Gómez M; Calvo I; González-Fernández MI; López-Montesinos B; Mesquida M; Adán A; Hernández MV; Maíz O; Atanes A; Bravo B; Modesto C; Díaz-Cordovés G; Palmou-Fontana N; Loricera J; González-Vela MC; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2017 Mar; 69(3):668-675. PubMed ID: 27696756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.
    Herlin T
    Core Evid; 2010 Jun; 4():181-9. PubMed ID: 20694074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.